We are 100% focused on ADCs and developing new process technology. To speed, simplify and significantly lower the production costs of the latest generation of anticancer blockbuster ADC drugs.
Join us for
the journey.
ADC BIO is an innovative biotechnology company.
Specialising in Antibody Drug Conjugates since 2010.
Forward thinking. Fast Moving.
DAY ONE.
Apr-10
ADC BIO incorporated.
GROUNDBREAKING.
Apr-11
1st generation Lock-Release patent filing – revolutionary aggregation control technology.
DRIVING VALUE.
Jan-13
Expansion funding for Technical Services Group.
RECOGNITION.
Jun-14
Award winner – Best for Innovation at BVCA.
Oct-14
First IND candidate developed.
PARTNERSHIPS.
Feb-15
Long-term FTE agreement signed with ADC Sector specialist.
Dec-15
Secure major pharma Lock-Release specific contract.
EXPERTISE.
Jan-16
5th IND Candidate developed for partner (supported 30% of all 2017 INDs).
INVESTMENT.
Sep-17
6500m2 Deeside GMP site secured by 3rd round investment.
Nov-17
Key Lock-Release patent granted in Europe and pending in the US.
PIONEERING.
Sep-18
Completion of Deeside manufacturing facility with integrated services.
Forward thinking. Fast Moving.
DAY ONE.
Apr-10
ADC BIO incorporated.
GROUNDBREAKING.
Apr-11
1st generation Lock-Release patent filing – revolutionary aggregation control technology.
DRIVING VALUE.
Jan-13
Expansion funding for Technical Services Group.
RECOGNITION.
Jun-14
Award winner – Best for Innovation at BVCA.
Oct-14
First IND candidate developed.
PARTNERSHIPS.
Feb-15
Long-term FTE agreement signed with ADC Sector specialist.
Dec-15
Secure major pharma Lock-Release specific contract.
EXPERTISE.
Jan-16
5th IND Candidate developed for partner (supported 30% of all 2017 INDs).
INVESTMENT.
Sep-17
6500m2 Deeside GMP site secured by 3rd round investment.
Nov-17
Key Lock-Release patent granted in Europe and pending in the US.
PIONEERING.
Sep-18
Completion of Deeside manufacturing facility with integrated services.
Specialists in BIO-CONJUGATE DISCOVERY, DEVELOPMENT & MANUFACTURING.